NCT04684563View on ClinicalTrials.gov

huCART19-IL18 in CD19+ Cancers

PHASE1RecruitingINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 6, 2021

Primary Completion Date

May 31, 2036

Study Completion Date

May 31, 2036

Conditions
Chronic Lymphocytic LeukemiaNon-hodgkin LymphomaAcute Lymphoblastic Leukemia
Interventions
BIOLOGICAL

huCART19-IL18

autologous Chimeric Antigen Receptor (CAR) T cells directed against the human CD19 antigen that also express human Interleukin 18 (IL-18)

Trial Locations (1)

19104

RECRUITING

University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

BlueWhale Bio (Cohort D only)

UNKNOWN

lead

University of Pennsylvania

OTHER